Izrael - hebrejski - Ministry of Health

teva israel ltd - amiloride as hydrochloride anhydrous; hydrochlorothiazide - טבליה - amiloride as hydrochloride anhydrous 5 mg; hydrochlorothiazide 50 mg - hydrochlorothiazide and potassium-sparing agents

Izrael - hebrejski - Ministry of Health

comex ltd - dihydrostreptomycin sulfate; procaine benzylpenicillin - תרחיף להזרקה - procaine benzylpenicillin 200 mg/ml; dihydrostreptomycin sulfate 250 mg/ml

Izrael - hebrejski - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - fluconazole - אבקה להכנת תרחיף - fluconazole 50 mg / 5 ml - fluconazole - fluconazole - cryptoccosis including cryptoccocal meningitis, systemic candidiasis including candidemia, mucosal candidiasis, vaginal candidiasis, dermatomycosis all as specified in leaflet.

Izrael - hebrejski - Ministry of Health

comex ltd - flunixin as meglumine - תמיסה להזרקה - flunixin as meglumine 50 mg/ml

Izrael - hebrejski - Ministry of Health

novartis israel ltd - ciclosporin - תמיסה לאינפוזיה - ciclosporin 50 mg/ml - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation.

Izrael - hebrejski - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - fulvestrant - תמיסה להזרקה - fulvestrant 50 mg/ml - fulvestrant

Izrael - hebrejski - Ministry of Health

romat ltd - aspartic acid; cyanocobalamin; d, l-acetylmethionine; fructose; glutamic acid; glycine; l- citrulline; l- lysine as hydrochloride; l- ornithine as hydrochloride; l-arginine; l-carnitine as hydrochloride; pyridoxine (vit b6) hydrochloride; sorbitol; thioctic acid - תמיסה להזרקה - thioctic acid 0.2 mg/ml; cyanocobalamin 0.03 mg/ml; glycine 1.5 mg/ml; aspartic acid 1.5 mg/ml; glutamic acid 1.5 mg/ml; fructose 50 mg/ml; sorbitol 80 mg/ml; pyridoxine (vit b6) hydrochloride 0.15 mg/ml; l- ornithine as hydrochloride 1.20 mg/ml; l- lysine as hydrochloride 0.50 mg/ml; l- citrulline 1.20 mg/ml; l-carnitine as hydrochloride 5.00 mg/ml; l-arginine 2.40 mg/ml; d, l-acetylmethionine 20.00 mg/ml

Izrael - hebrejski - Ministry of Health

teva israel ltd - risperidone - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - risperidone 50 mg/vial - risperidone

Izrael - hebrejski - Ministry of Health

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

Izrael - hebrejski - Ministry of Health

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate